Flutamide
- Generic Name
- Flutamide
- Brand Names
- Eulexin
- Drug Type
- Small Molecule
- Chemical Formula
- C11H11F3N2O3
- CAS Number
- 13311-84-7
- Unique Ingredient Identifier
- 76W6J0943E
- Background
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
- Indication
For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
- Associated Conditions
- Stage B2-C metastatic Carcinoma of the Prostate, Stage D2 metastatic Carcinoma of the Prostate
- Associated Therapies
- -
Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2003-04-18
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Target Recruit Count
- 105
- Registration Number
- NCT00003124
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 25
- Registration Number
- NCT00054106
- Locations
- 🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 361
- Registration Number
- NCT00002633
- Locations
- 🇨🇦
QEII Health Sciences Center, Halifax, Nova Scotia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 21
- Registration Number
- NCT00030654
- Locations
- 🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States
🇺🇸Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00028769
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 966
- Registration Number
- NCT00003026
- Locations
- 🇳🇱
St. Elisabeth Ziekenhuis, Tilburg, Netherlands
🇳🇱Academisch Ziekenhuis Groningen, Groningen, Netherlands
🇬🇧City General Hospital, Stoke-On-Trent, England, United Kingdom
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 397
- Registration Number
- NCT00004054
- Locations
- 🇺🇸
Lutheran General Cancer Care Center, Park Ridge, Illinois, United States
🇺🇸Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States
🇺🇸Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 67
- Registration Number
- NCT00023829
- Locations
- 🇨🇦
Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 1386
- Registration Number
- NCT00003653
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 306
- Registration Number
- NCT00002855
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.